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Abstract
Almost all animal models for chronic rejection (CR) after lung transplantation (LTx) fail to resemble the human situation. It
was our attempt to develop a representative model of CR in mice. Orthotopic LTx was performed in allografts receiving daily
immunosuppression with steroids and cyclosporine. Controls included isografts and mice only undergoing thoracotomy
(SHAM). Allografts were sacrificed 2, 4, 6, 8, 10 or 12 weeks after LTx. Pulmonary function was measured repeatedly in the
12w allografts, isografts and SHAM mice. Histologically, all allografts demonstrated acute rejection (AR) around the blood
vessels and airways two weeks after LTx. This decreased to 50–75% up to 10 weeks and was absent after 12 weeks.
Obliterative bronchiolitis (OB) lesions were observed in 25–50% of the mice from 4–12 weeks. Isografts and lungs of SHAM
mice were normal after 12 weeks. Pulmonary function measurements showed a decline in FEV0.1, TLC and compliance in the
allografts postoperatively (2 weeks) with a slow recovery over time. After this initial decline, lung function of allografts
increased more than in isografts and SHAM mice indicating that pulmonary function measurement is not a good tool to
diagnose CR in a mouse. We conclude that a true model for CR, with clear OB lesions in about one third of the animals, but
without a decline in lung function, is possible. This model is an important step forward in the development of an ideal
model for CR which will open new perspectives in unraveling CR pathogenesis and exploring new treatment options.
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Introduction
The long-term outcome of LTx is hampered by the occurrence
of CR. As a consequence, the long-term survival is still inferior
compared to other solid organs [1]. CR is morphologically
characterized by obliterative bronchiolitis (OB) and clinically by
an irreversible decline in forced expiratory volume in one second
(FEV1), named bronchiolitis obliterans syndrome (BOS). Many
animal models have been developed to study OB/BOS going from
heterotopic tracheal transplantations [2,3] to instillation of noxious
agents intratracheally [4,5].
The model most widely used to study OB, the heterotopic
tracheal transplantation, has some major shortcomings: the graft is
not placed in its physiological environment and is not in contact
with air; the trachea is a large airway while OB is per definition
small airway pathology and parenchyma and blood vessels cannot
be studied since they are absent. Obviously, diagnostic measures
such as broncho-alveolar lavage (BAL) and lung function
measurements are impossible in this model.
The ideal model to study OB/BOS should mimic the human
situation as much as possible, thus: an orthotopic LTx model
between major mismatched individuals receiving immunosuppres-
sion which leads to histological OB lesions and wherein, ideally,
lung function can be measured and BAL can be analyzed.
Orthotopic LTx has been described in large animals like dogs [6],
swine [7] and primates [8] allowing measurements of physiological
parameters but these species are more difficult to house and to
handle and are very expensive. Very recently, Jungraithmayr et al.
described a new rat model of CR wherein orthotopically
transplanted lungs show fibroproliferation of the airways [9].
However, the lack of potential to study mechanistic pathways due
to the shortage of specific antibodies, transgenic and knock-out
strains of this species may limit their use in the study of BOS
pathogenesis. The only species that may hold this potential is the
mouse, and, although its size seriously complicates surgery, this
species indeed offers a large variety of transgenic strains and
available antibodies.
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In 2007, Okazaki et al. were the first to describe orthotopic LTx
in mice [10]. This technique opened new perspectives in the
search for an ideal model for BOS since it mimics the human
situation well and BAL and lung function might be used in these
animals. The aim of our study was therefore to first develop a
murine OB/BOS model after orthotopic LTx in major MHC
mismatched mice receiving immunosuppression with OB lesions
detectable in the allograft and secondly, to explore the potential of
pulmonary function measurements and BAL in this model.
Methods
Study Design
The study design is illustrated in Figure 1. Since pilot
experiments showed clear OB lesions in some allografted mice
under immunosuppression, we performed LTx in both allografts
and isografts. Allografts were sacrificed after 2, 4, 6, 8 or 10 weeks
(n = 5 per group). To explore the potential of lung function
measurements (according to the definition of BOS) a separate
group of allografts underwent two-weekly, repeated pulmonary
function measurements and was sacrificed at 12 weeks after LTx
(n = 10). To assess the influence of LTx surgery alone, a group of
isografts (n = 9) also underwent two-weekly lung function mea-
surements and were sacrificed afterwards. To determine the
influence of the thoracotomy, without LTx, lung function of
SHAM mice (n = 9), only undergoing thoracotomy, was also
measured repeatedly during 12 weeks.
Animals
All animals were purchased from Janvier Elevage (France).
Male, 25–30 gr C57BL6 mice (H-2Kb) were used as recipients.
Male BALB/C mice (H-2Kd) served as donors for allografts,
C57BL6 mice served as donor for isografts. SHAM mice
(C57BL6) only underwent thoracotomy. The protocol was
approved by the local Ethics committee (Ethische commissie
proefdierencentrum Katholieke Universiteit Leuven, nu 075/2008)
and all animals received humane care in compliance with ‘‘The
Principles of Laboratory Animal Care’’ formulated by the
National Society for Medical Research and the ‘‘Guide for the
Care and Use of Laboratory Animals’’ published by the National
Institutes of Health (NIH Publication No. 86-23, revised 1996).
Orthotopic LTx
Orthotopic LTx was adapted from the technique described by
Jungraithmayr et al. [11]. Donor mice were anesthetized with a
mixture of medetomidine (1 mg/kg) and ketamine (75 mg/kg)
intraperitoneally. A tracheostomy was performed and the mouse
was connected to a ventilator (UNO microventilator UMV-03,
UNO Roestvaststaal, Zevenaar, The Netherlands). Abdomen and
thorax were opened and the lungs were flushed with 5 ml
PerfadexH (Vitrolife, Go¨teborg, Sweden) through the arteria
pulmonalis. Afterwards, the heart-lung block was excised with
inflated lungs and put on ice. The hilum of the left lung was
dissected and artery, vein and bronchus were cuffed. Afterwards,
the recipient was anesthetized with isoflurane (IsobaH, Schering-
Plough, Uxbridge, UK) in an induction box. The animal was
intubated and connected to the ventilator with a mixture of 50%
O2, 50% air and 2.5% isoflurane. After thoracotomy, artery, vein
and bronchus were separated from each other and 10-0 ligatures
were placed around the structures. Microvascular clamps were put
on artery and vein. First the vein was anastomosed, then the artery
and subsequently the bronchus. The clamps were released (first
vein, then artery) and the lung inflated. Hereafter, the chest was
closed and the animal could wake up. Pain medication, with
Figure 1. Study design. Allograft: from BALB/C to C57BL6, isografts from C57BL6 to C57BL6. q represents the time point of lung function
measurement, at the end of each time bar animals were sacrificed and BAL and histology were performed.
doi:10.1371/journal.pone.0029802.g001
Model Chronic Rejection Lung Transplantation
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29802
buprenorphine (0.1 mg/kg every 8 hours during 3 days, Temge-
sicH, Schering Plough, UK) was given as soon as animals regained
full consciousness.
Immunosuppressive treatment
Several pilot experiments were performed to find a balanced
immunosuppressive scheme to suppress AR but let OB lesions
develop. Different dosages of cyclosporine (5–50 mg/kg/d), based
on human clinic and a mouse model of chronic heart rejection
[12], were tested until blood levels resembling human blood levels
of 200–300 mg/l were obtained. The dose-response curve of
different dosages of cyclosporine in healthy animals is illustrated in
Figure 2. Since cyclosporine alone was not sufficient to suppress
severe AR, steroids were added to the immunosuppressive scheme.
Tapering the dosage of steroids and treating the donor with
steroids, like in patients, did not make a difference in the severity of
AR lesions 2 weeks after LTx. All these experiments led to our
current immunosuppressive scheme of 10 mg/kg/d cyclosporine
(SandimmunH, Novartis, Vilvoorde, Belgium)+1.6 mg/kg/d
methylprednisolone (Solu MedrolH, Pfizer, Brussels, Belgium)
subcutaneously until sacrifice.
Repeated pulmonary function measurements
FEV0.1 in mice was measured repeatedly with the Buxco-
Forced Pulmonary ManeuversH (Buxco research systems,
Wilmington, North Carolina USA). Intubation and pulmonary
function measurement were performed as described previously
[13]. Three maneuvers were performed. First the Boyle’s law FRC
maneuver was performed wherein the animal breathes against a
closed valve to measure the Functional Residual Capacity (FRC).
Then the quasistatic pressure volume maneuver is performed,
wherein the lungs are inflated to 30 cm H2O and then slowly
exhaled to a negative pressure of 230 cm H2O, to measure,
amongst others, residual volume (RV) and total lung capacity
(TLC). And then the fast flow volume maneuver is performed,
wherein the lungs are first inflated to 30 cm H2O and then quickly
exhaled, which allows the measurement of FEV0.1. Pulmonary
function was performed one week before LTx/thoracotomy and
every two weeks thereafter until 12 weeks after LTx.
BAL and Histology
Blood was drawn from the vena cava for the evaluation of
cyclosporine blood levels (sequential enzyme immunoassay,
DimensionH RXL, Siemens Medical solutions, Diamond diagnos-
tics, USA) at time of sacrifice. Immediately afterwards, BAL was
performed in left and right lung separately with 4 aliquots of
0.5 ml sterile saline per lung. Total cell counting was performed
using the CountessTM Automated Cell Counter (Invitrogen,
Merelbeke, Belgium) and cytospins (Shandon) with May-Gru¨n-
wald-Giemsa staining were made for differential cell counting.
After BAL, the heart-lung block was excised and fixed in 4%
paraformaldehyde at a constant hydrostatic pressure of 20–25 cm
fluid column for at least 20 minutes and embedded in paraffin.
Sections were stained with haematoxylin-eosin to evaluate lung
damage and inflammation by a pathologist (E.V.). Sirius Red
staining was performed to visualize collagen and fibrosis.
Immunohistochemistry for CD3 was performed on a representa-
tive sample of each type of lesion. The primary antibody for CD3
(DAKO, Heverlee, Belgium) was applied at a dilution of 1/20.
The signal was visualized using 3,39-diaminobenzidine tetrahy-
drochloride, producing a brown stain at the site of the reaction.
Statistical analyses
Statistics were performed with Graphpad Prism Software
version 4.1 (San Diego, CA, USA) and SAS 9.1 (SAS Institute,
NC, USA). General linear mixed models, one way ANOVA with
post hoc Tukey tests, Kruskal Wallis and t-tests were used where
appropriate; p,0.05 was considered significant.
Results
Survival and general health
Success rate of LTx, with mice succesfully waking up, now
reaches up to 90%. No difference in success was noted between
isograft and allograft LTx. Weight evolution in the 3 groups is
illustrated in Figure 3. Roughly, the weight of SHAM and isografts
increased constantly during the post LTx period. Allografts,
although somewhat heavier at the beginning of the experiment,
lost 1.8 g (0.25–2.05) of bodyweight after the LTx and only
Figure 2. Dose-response curve of Cyclosporine in healthy
animals after daily subcutaneous injection during two weeks.
doi:10.1371/journal.pone.0029802.g002
Figure 3. Weight evolution of isografts, allografts and SHAM
mice. POD: post-operative day; LTx: lung transplantation; SHAM: only
thoracotomy.
doi:10.1371/journal.pone.0029802.g003
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regained their initial weight slowly. Body weight increased more in
isografts and SHAM mice than in allografts (p,0.0001).
Of the successful operated mice (surviving more than 24 hours),
all mice not undergoing pulmonary function measurement
survived until sacrifice after 2, 4, 6, 8 or 10 weeks. All SHAM
mice survived the consecutive pulmonary function measurements.
In the isograft group two mice died: one mouse died after a very
difficult recovery from the first pulmonary function measurement
after LTx (POD 14), the other mouse died 5 days after the second
lung function measurement after LTx (POD 33). In the allograft
group 3 mice died during the 12w follow-up: one after a difficult
recovery from the second pulmonary function measurement after
LTx (POD 29), one each 4 and 5 days after the third measurement
after LTx (POD 46 and 47). Survival was comparable between the
three groups (p = 0.22).
Pulmonary function measurements
FEV0.1 showed an important decline in the allografts from 0.98
(0.89–1.12) ml before LTx to 0.79 (0.63–0.84) ml two weeks after
LTx. In the isografts and SHAM mice the initial decline was very
small from 0.78 (0.75–0.88) ml to 0.75 (0.69–0.91) ml in the
isografts and from 0.97 (0.85–1.05) ml to 0.96 (0.81–1.07) ml in
the SHAM mice. This decline was different between the 3 groups
(p = 0.0002) and bigger in allografts than in SHAM mice
(p,0.001) and isografts (p,0.001). From then on, FEV0.1 of
allografts increased and fully recovered after 12 weeks. FEV0.1
from both isografts and SHAM mice restored to pre-LTx values
within 4 weeks after LTx. After this initial decline we could see a
significant difference in FEV0.1 evolution between the groups with
a bigger FEV0.1 increase after LTx in allografts than in the other
groups (p = 0.0002).
TLC showed also the biggest decline in the allografts from 1.06
(1.00–1.28) ml before LTx to 0.82 (0.74–0.90) ml two weeks after
LTx. Decline in TLC was different in the 3 groups (p = 0.0008).
After LTx, TLC followed about the same trends as FEV0.1 with
again the biggest increase in the allografts (p = 0.0313).
The same was true for compliance (Cchord): biggest decline in
the allografts (p = 0.001) and after LTx the biggest increase was
seen in the allografts (p = 0.0008). FEV0.1, TLC and Cchord
evolution of the 3 groups are shown in Figure 4.
Broncho-alveolar lavage
BAL was performed at time of sacrifice (2–12 weeks after LTx).
Total cell counts of the right native lungs were: 432,500 (257,500–
597,500) cells/ml in the allografts, 70,000 (55,000–185,000) cells/
ml in the isografts and 162,500 (525,00–270,000) cells/ml in the
SHAM mice. These differences were statistically significant
(p = 0.0008) and post hoc tests showed a significant difference in
allografts vs isografts (p,0.01) and allografts vs SHAM (p,0.05).
Neutrophil percentages of the right lungs were not statistically
different between the 3 groups: 0 (0–4)% for the allografts, 0 (0–
6)% for the isografts and 0 (0–0.5) % in the SHAM mice.
Macrophage percentages were also not different between the
groups (p =NS).
Total cell counts of the left lungs were: 50,000 (20,000–85,000)
cells/ml in the isografts and 85,000 (47,250–122,500) cells/ml in
the SHAM mice (p =NS). Unfortunately, BAL was technically not
possible in most of the allografted left lungs.
Histology
As expected, no histological changes were found in SHAM mice
(Figure 5). Isografted lungs also looked normal after 12 weeks
showing no inflammation, fibrosis etc. (Figure 5). Native right
Figure 4. Lung function evolution of the different groups.
Decline in FEV0.1 and TLC from before transplantation to 2 weeks after
transplantation was significantly different between the groups (FEV0.1:
p = 0.0002; TLC: p = 0.0008) and afterwards the increase in both these
parameters was biggest in allografts (FEV0.1: p = 0.0002; TLC: 0.0313).
FEV0.1: forced expiratory volume in 0.1 second; TLC: total lung capacity;
Cchord: compliance; POD: post-operative day.
doi:10.1371/journal.pone.0029802.g004
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lungs of allografts (and isografts) looked also completely normal
(Figure 5).
In the allografts, however, clear histological changes were found
and overall, Sirius Red staining showed more collagen in the
allografts compared to the native right lungs. After two weeks,
inflammation of the broncho-vascular axes, within the walls of
vessels and airways, was seen in all allografts. The respective
lumina were patent and the inflammatory cells consisted mainly of
lymphocytes. The epithelium was preserved and the alveolar
parenchyma showed preserved architecture and looked functional
(Figure 6). Some oedema, at times some hemorrhage was also seen
however. All together, these lesions histologically resemble A and
B grade lesions of AR as described by Stewart et al. [14].
At later time-points (4–12 weeks) we observed a clear distinction
in two types of lesions. One fourth to half of the samples,
depending on the time-point, showed very distinct OB lesions with
fibrotic plugs growing into the airways. The epithelium of these
airways is mainly normal and only damaged where the fibrotic
plug is growing into the lumen. The surrounding parenchyma
showed postobstructive changes with aspects of endogenous lipid
pneumonia with foamy macrophages and interstitial inflammation
(Figure 7). Polarized Siriud red images clearly demonstrate the
absence of fibrosis in the parenchyma (Figure 8). OB lesions
showed clear evolution over time going from immature lesions
mainly existing of fibrine without cells to organizing lesions
containing cells and angiogenesis to end-stage, epitheliazed lesions
without inflammation and with dense collagen staining (Figure 7).
Polarization of the Sirius Red slides clearly shows a distinction in
younger, more reddish collagen structures and older, more white
collagen (Figure 7C).
The other lungs showed AR lesions as described above and over
time, inflammation diminished and remarkebly at 12 weeks after
LTx 2/3 of the lungs showed normal histology with mimimal rest
damage seen in pigmented macrophages (Figure 6).
A combination of both types of lesions, with fibrotic plugs,
enlargement of the broncho-vascular axes and functional paren-
chyma, was seen in one animal. Distribution of the lesions at the
different time points is given in Figure 9. CD3 immunohistochem-
istry confirmed the presence of lymphocytes in the lymphocytic
Figure 5. Histology of SHAM mice (top), isografts (middle) and
native right lungs from allografts (bottom) 12 weeks after
thoracotomy/lung transplantation respectively. HE staining
showed normal histology.
doi:10.1371/journal.pone.0029802.g005
Figure 6. Histology of allografts showing lymphocytic bronchiolitis lesions. A) early after transplantation (2w) and B) late after
transplantation (12w). Left side: HE staining, right side: Sirius Red (SR) staining. 2w after transplantation allografts showed enlargement of broncho-
vascular axes with infiltration of lymphocytes around airways (Aw) and blood vessels (Bv). Sirius Red staining shows collagen both perivascular as
peribronchial. After 12w, lungs completely recovered with some leftover damage seen in pigmented macrophages (arrow).
doi:10.1371/journal.pone.0029802.g006
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bronchiolitis type of lesions (Figure 10). In the OB lesions an
occasional lymphocyte was seen around the airways. Of the 32
animals in these series, 3 mice showed necrosis of the allograft,
probably due to an early event. These mice were not taken into
account in the distribution of rejection lesions.
Cyclosporine serum levels
Serum level of cyclosporine was assessed in 22 mice distributed
over the different time points. Median serum level of cyclosporine
was 392 (248–624) mg/l, comparable to human serum levels.
Cyclosporine levels did not differ between time-points after LTx
(p = 0.34). However, retrospectively comparing cyclosporine levels
in mice showing OB and non-OB lesions showed a significant
difference (p= 0.015) with lower cyclosporine levels in the mice
showing OB lesions (247 (222–422) mg/l) than in mice showing
lymphocytic bronchitis lesions (496 (361–720) mg/l).
Discussion
The present study was designed to develop a murine model of
BOS resembling as much as possible the human situation wherein
mice receive a major mismatch graft in which histological OB
lesions develop during daily immunosuppression. The potential of
repeated pulmonary function measurements and BAL were also
examined in this model. Very distinct histological OB lesions were
Figure 7. Histology of allografts showing obliterative bronchiolitis. A) early after transplantation (4w) and B+C) late after transplantation
(10w). HE staining and Sirius Red (SR) staining are represented in A and B. In the right panel of C polarized SR images are shown. OB lesions are
indicated with arrow. Early after transplantation, fibrotic plugs are poor in cells and show little collagen staining. Later after transplantation, cells are
more prominently present in the fibrotic plugs and intensive collagen staining of plugs is seen. The polarized images clearly indicate the difference in
younger, more reddish collagen and older, more white collagen.
doi:10.1371/journal.pone.0029802.g007
Figure 8. Detail of the parenchyma of allografts showing
obliterative bronchiolitis late after transplantation (10w). Left:
non-polarized Sirius Red staining; right: polarized Sirius Red. The
polarized image clearly shows that fibrosis is absent in the parenchyma.
The small amounts of polarized structures indicate native framework.
doi:10.1371/journal.pone.0029802.g008
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seen in these allografts and repeated lung function measurements
were feasible. A true model of BOS with decline in pulmonary
function and changes in BAL cellularity was, however, not
established. Nevertheless, this model looks very promising in
unraveling CR pathogenesis and in exploring new treatment
options.
The orthotopic mouse LTx model has so far mainly been used
in the study of acute rejection [15] and ischemia-reperfusion injury
[16;17], both risk factors for BOS. Since BOS is the main cause of
late mortality/morbidity after LTx, the development of a new
BOS model starting from orthotopic LTx is a logical step. Very
recently, Fan et al. were the first to describe OB lesions in
allografted mice [18]. The OB lesions described are very similar to
those in our model and although proportions of mice showing OB
lesions are slightly different, about the same trends are seen with
about one fourth to half of the mice showing OB. Histology images
of the whole lung, however, are lacking in their paper although
these allow the asssessment of lesion distribution, not possible in
humans. Also lymphocytic bronchiolitis lesions have not been
described in detail while these lesions gained interest in long-term
survival after LTx [19]. Some other major differences with our,
independently developed, model are present. While they used a
minor mismatch combination of mice without immunosuppres-
sion, our aim was to really mimic the human situation wherein
major mismatch combinations of donor/recipient are predomi-
nant and all allografted animals receive immunosuppression. Since
mimicking the human situation was our primary goal it was our
attempt to develop a true BOS model with BAL and lung function
measurements and, for now, not to look at pathological
mechanisms.
Several hurdles needed to be taken to develop this model. The
surgical technique had to be adopted and a good immunosup-
pressive scheme needed to be developed since we know from the
literature that, if no immunosuppression is given to major
Figure 9. Distribution of the histological lesions of the airways
at the different time points after lung transplantation.
Perivascular lesions were not taken into consideration.
doi:10.1371/journal.pone.0029802.g009
Figure 10. CD3 immunohistochemistry of lymphocytic bron-
chiolitis and obliterative bronchiolitis lesions. A) lymphocytic
bronchiolitis and B) obliterative bronchiolitis lesions both early (4w) and
late (10w). Brown cells represent CD3 positive cells. Aw: airway, dotted
lines represent approximate contours of the fibrotic plugs.
doi:10.1371/journal.pone.0029802.g010
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mismatched mice, the allograft undergoes severe AR and necrosis
after 4 weeks [20].
This study has some shortcomings. 3/32 mice showed necrosis
of the graft probably due to malfunctioning of the graft and could
not be evaluated in the scope of rejection. Although patients with
BOS have an irreversible decline in FEV1, this decline could not
be reproduced in mice and pulmonary function measurement is
not the good tool to diagnose OB lesions since lung volumes
restore to normal values over time in allografted mice. The same
phenomenon can be seen in mice undergoing a left pneumonec-
tomy. Voswinckel et al. indeed showed that 21 days after left
pneumonectomy, mid-expiratory airflow (a parameter for lung
volume) reached control values [21]. This demonstrates the
enormous growth capacity of the right lung in adult mice. The
decline in lung function early after LTx in the allografts, however,
demonstrates that lung function measurements may demonstrate
signs of AR as the decline in different parameters was much more
pronounced in allografts compared to isografts and SHAM mice.
The differences in decline early after LTx and in recovery
afterwards can partly be explained by a difference in weight
between allografts and isografts (and SHAM) at the beginning of
the experiment. Mice were transplanted when weighing 25–30 g
but an exact weight match between the groups was never aimed
for. And since pulmonary function of the mice is measured exactly
1 week before they are being transplanted and only 2 mice a day
can be transplanted, day-variability can also partly explain these
baseline differences.
BAL was unfortunately not possible in the transplanted
allografts, although histology showed open anastomoses (data not
shown) and fixating the lung with paraformaldehyde was possible
indicating that the anastomoses were indeed open. So far, no
conclusion can be drawn about which cells occur in the airways
and future experiments should be performed to optimize BAL
sampling in these allograft lungs.
The OB lesions we demonstrated, though, were very clear and
confirm the feasability of achieving these lesions in transplanted
mice. OB lesions occurred in 25–50% of the mice from 4 weeks
on, depending on the time-point after LTx. The strength of our
study is that we can see a distinct evolution in the OB lesions over
time. Lesions evolve from pure fibrinous to active, cell-containing
lesions to inactive, end-stage, pure collagenous lesions which stain
intensively with Sirius Red. By polarizing the Siriud red stained
slides, a distinction in young and older collageneous structures can
be seen within these fibrotic plugs demonstrating their evolution.
Evolution of these lesions over such a long period of time (12
weeks) has never been described before and this evolution throws
new light over the pathogenesis of CR in patients since obtaining
consecutive biopsy samples in patients is nearly impossible. A
remarkable difference with human OB pathology is that the
epithelium in our mouse model is more preserved. In fact, the
epithelium is only damaged where the fibrotic plug is growing into
the airway lumen while in human OB, epithelial damage has been
suggested to be the trigger of the cascade leading to OB [22].
A clear distinction can be made in mice OB lungs (25–50%) and
non-OB-lungs (50–75%) and this from 4 weeks after LTx. Looking
at the time-distribution of the lesions we saw that at 2 weeks after
LTx, all lungs showed the same lesions so the question remains
why some mice develop OB and other mice do not develop OB
and even regain normal histology after 12 weeks. In patients,
different risk factors for BOS have been identified like AR, reflux,
Pseudomonas colonization and HLA mismatching [23]. Extrap-
olating this to mice we can assume that the degree of HLA
mismatching is not the determining factor for developing one type
of lesion or another since the mismatch is identical in all our
animals. The mice are housed in a conventional animal facility
meaning that infections and colonizations can not completely be
ruled out. However, histology showed no infection of the lungs
except in one animal and health status of the mice was negative for
all viruses/bacteria/parasites according FELASA (Federation of
European Laboratory Animal Sciences Associations) recommen-
dations (www.felasa.eu/recommendations). Two weeks after LTx,
all lungs showed AR lesions but later on, only 25–50% of the mice
developed CR lesions meaning that the development of AR can
not be the only explanation for the development of CR. Looking at
cyclosporine serum levels though, a difference was seen with lower
cyclosporine levels in mice having OB lesions. Although animals
are genetically identical, the animals remain different individuals
and pharmacokinetics of cyclosporine seem to be different. This
difference might hold the key why not all animals develop OB.
In conclusion, we can say that a murine model for CR after LTx
has been developed in one third of our animals with multiple
immunosuppressants, but not for true BOS with declining lung
function and BAL cellular changes. This is a very important step
forward in the development of a good animal model for CR which
will certainly help in unraveling the pathogenesis and exploring
new treatment options of this complication which significantly
hampers long-term survival of LTx patients.
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